Pharmaceutical

Bluejay touts positive data for chronic hepatitis D treatment

The biopharma shared preliminary Phase II data at EASL for its IgG1 monoclonal antibody, BJT-778

Jun 6, 2024 - 04:00
Bluejay touts positive data for chronic hepatitis D treatment
The biopharma shared preliminary Phase II data at EASL for its IgG1 monoclonal antibody, BJT-778
Read the original article

Tags:

Previous Article

Flapping frequency of birds, insects, bats and whales described by universal equ...

Next Article

Scientists push for ‘greener’ drugs in published study

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Conflict means millions of children are missing vaccinations, UN says

Conflict means millions of children are missing vaccina...

Jul 16, 2024

STAT+: Pharmalittle: Deadline looms for drugmakers to negotiate with Medicare; GOP senator probes 340B program at two hospitals

STAT+: Pharmalittle: Deadline looms for drugmakers to n...

Sep 30, 2023

Adcendo and Multitude ink ADC deal potentially worth $1bn

Adcendo and Multitude ink ADC deal potentially worth $1bn

Aug 21, 2024